Skip to main content

Table1 Correlation between NEK2 expression and clinicopathological parameters

From: NEK2 promotes the migration and proliferation of ESCC via stabilization of YAP1 by phosphorylation at Thr-143

 

Higher expression of NEK2 (n = 57)

Lower expression of NEK2 (n = 46)

P

Sex, Male (%)

49 (86.0)

36 (78.3)

0.446

Age (mean (SD))

66.61 (9.47)

64.61 (7.40)

0.243

Size (mean (SD))

4.70 (1.79)

4.83 (1.77)

0.717

Location (%)

  

0.779

 Middle

46 (80.7)

39 (84.8)

 

 Others

10 (19.3)

8 (15.2)

 

Morphology (%)

  

0.111

 Plaque

11 (19.3)

5 (10.9)

 

 Fungoid

12 (21.1)

14 (30.4)

 

 Ulcerative

0 (0.0)

3 (6.5)

 

 Medullary

34 (59.6)

24 (52.2)

 

Grade (%)

  

0.001

 G1

2 (3.5)

13 (28.3)

 

 G2

40 (70.2)

28 (60.9)

 

 G3

15 (26.3)

5 (10.8)

 

Invasion depth (%)

  

0.557

 Submucosal

1 (1.8)

2 (4.3)

 

 Muscular

14 (24.6)

14 (30.4)

 

 Serosa

42 (73.7)

30 (65.2)

 

Lymph node metastasis

  

0.029

 Yes

34 (59.6)

17 (37.0)

 

 No

23 (40.4)

29 (63.0)

 

T stage (%)

  

0.462

 T1

1 (1.8)

2 (4.3)

 

 T2

13 (22.8)

13 (28.3)

 

 T3

41 (71.9)

31 (67.4)

 

 T4

2 (3.5)

0 (0.0)

 

N stage (%)

  

0.065

 N0

23 (40.4)

29 (63.0)

 

 N1

20 (35.1)

11 (23.9)

 

 N2

10 (17.5)

6 (13.0)

 

 N3

4 (7.0)

0 (0.0)

 

Metastasis

0

0

 

AJCC* stage (%)

  

0.001

 I

1 (1.8)

5 (10.9)

 

 II

22 (38.6)

24 (52.2)

 

 III

27 (47.4)

17 (37.0)

 

 IV

7 (12.3)

0 (0.0)

 
  1. *AJCC The 8th Version of American Joint Committee on Cancer